Surfactant phosphatidylcholine metabolism in neonates with meconium aspiration syndrome

J Pediatr. 2006 Nov;149(5):634-9. doi: 10.1016/j.jpeds.2006.07.027.

Abstract

Objective: Because meconium directly inhibits surfactant function, we sought to determine the effect of meconium on endogenous surfactant synthesis and clearance.

Study design: We studied surfactant phosphatidylcholine kinetics with the use of stable isotopes in 11 newborn infants with meconium aspiration syndrome (MAS) who required extracorporeal membrane oxygenation (ECMO). For comparison we studied 6 neonates with persistent pulmonary hypertension (PPHN) on ECMO and 10 term neonates ventilated for non-pulmonary indications and not on ECMO. All patients received a 24-hour [U- 13C]glucose infusion as precursor for the palmitic acid in surfactant phosphatidylcholine.

Results: In the meconium group, the maximal 13C-incorporation in phosphatidylcholine (PC) was half of that in controls (0.09 +/- 0.01 vs 0.18 +/- 0.03 atom percent excess [APE], P = .027). There was a trend toward lower surfactant synthesis in the MAS group (3.3 +/- 0.7%/day) and PPHN group (2.6 +/- 0.3%/day) compared with controls 8.0 +/- 2.4%/day, P = .058). Significantly lower PC concentrations in tracheal aspirates were found in the MAS group (4.4 +/- 2.6 mg/mL) and PPHN group (3.6 +/- 2.0 mg/mL) compared with controls (12.8 +/- 2.6 mg/mL, P = .01). Endogenously synthesized surfactant had a similar half-life in all groups, ranging from 63 to 98 hours.

Conclusion: We conclude that surfactant synthesis is disturbed and that surfactant PC concentrations are low in infants with MAS on ECMO.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Case-Control Studies
  • Combined Modality Therapy
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Glucose / administration & dosage
  • Glucose / analogs & derivatives
  • Half-Life
  • Humans
  • Infant, Newborn
  • Infusions, Intravenous
  • Male
  • Meconium Aspiration Syndrome / metabolism*
  • Meconium Aspiration Syndrome / physiopathology
  • Meconium Aspiration Syndrome / therapy
  • Palmitic Acids / metabolism
  • Persistent Fetal Circulation Syndrome / metabolism
  • Phosphatidylcholines / metabolism*
  • Phosphatidylcholines / therapeutic use*
  • Pulmonary Surfactants / metabolism*
  • Pulmonary Surfactants / therapeutic use*
  • Respiration, Artificial
  • Time Factors
  • Trachea / metabolism
  • Treatment Outcome
  • Urea / administration & dosage
  • Urea / analogs & derivatives
  • Urea / blood

Substances

  • Palmitic Acids
  • Phosphatidylcholines
  • Pulmonary Surfactants
  • glucosylurea
  • Urea
  • Glucose